---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-007580"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2023-03-13T23:59:59+00:00"
generated_at: "2026-06-18T04:31:47.076672+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amylyx reports $22.2M full-year product revenue; net loss $198.4M

## Summary
- Q4 net product revenue $21.9M; full-year 2022 net product revenue $22.2M from RELYVRIO/ALBRIOZA sales.
- Net loss for 2022 was $198.4M ($3.39 per share) vs. $87.9M in 2021; cash & short-term investments $346.9M.
- Phase 3 PHOENIX trial fully enrolled (664 participants); topline data expected mid-2024.
- EU MAA regulatory review ongoing; company now expects CHMP opinion mid-2023 and decision Q3 2023 at earliest.
- Karen Firestone appointed to Board of Directors effective March 16; raised $230.6M net in October 2022 public offering.

## SEC filing metadata
- accession: 0000950170-23-007580
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2023-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000095017023007580/0000950170-23-007580-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000095017023007580/amlx-20230313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-007580
- JSON: https://secwatch.observer/filing/0000950170-23-007580.json
- Plain text: https://secwatch.observer/filing/0000950170-23-007580.txt

## Key facts
- Earnings Releases
  Amylyx Pharmaceuticals, Inc. reported the fourth quarter and full year ended December 31, 2022 results: revenue $21.9 million, net income $42.7 million, or $0.65 per share.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Revenue: $21.9 million
  - Net income: $42.7 million, or $0.65 per share
  - Result: reported results
  source text: For the three months ended December 31, 2022, net product revenue was $21.9 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658551/000095017023007580/0000950170-23-007580-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.